Garsorasib

格索雷塞

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameGarsorasib
Drug Alias Name格舒瑞昔安方宁D-1553
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/11/05
Country/TerritoryUnited StatesTaiwanAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInventisbio Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInventisbio Co Ltd
Inactive CompaniesWuxi Sta Pharmaceutical Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A